BookmarkSubscribeRSS Feed
AndreyMyslivets
Obsidian | Level 7

Hello everybody!

Could you please help me with calculations and script?

The main endpoint analysed using proportion difference.

I have the following information:

1. alpha = 0.05 one-sided;

2. power = 0.80;

3. a non-inferiority margin equal -0.20 (greater is better);

4. an actual difference between treatment groups (test drug - reference drug) planned as -0.05

5. groups weight is 1:1;

6. an overall response rate of reference drug is 38% from articles.

7.  stopping rules O’Brien-Fleming ;

8. number of stages is 2:

      1 interim at 75% of patients

      1 final

I have a draft skript:

proc seqdesign altref=<...>

               pss

               stopprob

               errspend

               ;

   OneSidedOBrienFleming: design

            nstages = 2

            method = obf

            alpha = <...>

            beta = 0.20

            info = cum(0.75 1);                        

   samplesize model=twosamplefreq (TEST=PROP <...> );

run;

Could You please help to impliment the correct data instead of <...>

Thanks!

Andrey

2 REPLIES 2
Damir
Calcite | Level 5

Dear andrey,

i have the same problem with a margin equal to -0.04 and 0 for actual difference between treatement.

Did you find a solution to your problem ?

Thinks

Damir

 

kekeke
Calcite | Level 5

As I know, SEQDESIGN does not currently have options to directly support group sequential non-inferiority, superiority, or equivalence trials. 

SAS Innovate 2025: Register Now

Registration is now open for SAS Innovate 2025 , our biggest and most exciting global event of the year! Join us in Orlando, FL, May 6-9.
Sign up by Dec. 31 to get the 2024 rate of just $495.
Register now!

What is ANOVA?

ANOVA, or Analysis Of Variance, is used to compare the averages or means of two or more populations to better understand how they differ. Watch this tutorial for more.

Find more tutorials on the SAS Users YouTube channel.

Discussion stats
  • 2 replies
  • 2187 views
  • 0 likes
  • 3 in conversation